Denali Therapeutics Inc.
DNLI · XNASCIK 1714899fmd_1ECW73VNJTS0NDH1W979QZCZCBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 129 | 27 | 336 | 49 | 108 | 331 | 0 | 0 |
| Research and development | 76 | 74 | 143 | 193 | 213 | 265 | 359 | 424 | 396 | 419 |
| Total operating expenses | 87 | 90 | 176 | 240 | 273 | 344 | 449 | 527 | 502 | 555 |
| Operating income | (87) | (90) | (46) | (213) | 63 | (296) | (341) | (197) | (487) | (555) |
| Interest and investment income | – | – | – | – | – | – | 15 | 52 | 65 | 43 |
| Other non-operating income (expense) | 1 | 2 | 10 | 15 | 9 | 5 | 15 | 52 | – | – |
| Income tax expense | – | 0 | 0 | (0) | 1 | (1) | 0 | 0 | 0 | 0 |
| Net income | (87) | (88) | (36) | (198) | 71 | (291) | (326) | (145) | (423) | (513) |